Most promisingly, a phase I clinical trial in which genome editing is being used to treat transthyretin amyloidosis with polyneuropathy by targeting the TTR gene (encoding transthyretin, a thyroxine and retinol transport protein) in the liver (56) is already under way. Here, TTR is linked to amyloidosis.